Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
5 participants
INTERVENTIONAL
2012-03-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vigil™ Vaccine
Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
Vigil™ Vaccine
Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
Bevacizumab
Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vigil™ Vaccine
Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
Bevacizumab
Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Previous randomization to Gradalis, Inc. protocol CL-PTL 105; observation arm (Group B) or patients with vaccine prepared for CLPTL 105 but not otherwise qualifying.
3. Recurrent cisplatinum resistant/refractory disease (defined as the appearance of any measurable or evaluable lesion or as asymptomatic CA-125 levels greater than 100 u/mL at two consecutive measurements with no intervening therapy.
4. Successful manufacturing of 4 vials of Vigil™ vaccine.
5. Recovered from all clinically relevant toxicities related to prior therapies.
6. ECOG PS 0-2 prior to Vigil™ vaccine administration.
7. Normal organ and marrow function as defined below:
1. Absolute granulocyte count ≥1,500/mm3
2. Absolute lymphocyte count ≥ 200/mm3
3. Platelets ≥100,000/mm3
4. Total bilirubin ≤1.5 x ULN
5. AST(SGOT)/ALT(SGPT)/alkaline phosphatase ≤2.5 x ULN
6. Creatinine \<1.5 mg/dL
7. INR \< 1.5
8. Baseline blood pressure must be under 140/90
9. Urine protein-to-creatinine ratio \< 1.0 mg/dL.
10. Patients must be off all "statin" drugs for ≥ 2 weeks prior to initiation of therapy.
11. Ability to understand and the willingness to sign a written informed protocol specific consent.
Exclusion Criteria
2. Major surgery within 6 weeks or minor surgery within 2 weeks of receiving bevacizumab.
3. Patient must not have received any other investigational agents within 4 weeks prior to study entry.
4. Patients who require parenteral hydration of nutrition and have evidence of partial bowel obstruction or perforation.
5. Patients with history of brain metastases.
6. Patients with compromised pulmonary disease.
7. Short term (\<30 days) concurrent systemic steroids ≤ 0.25 mg/kg prednisone per day (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded.
8. Prior splenectomy.
9. Prior malignancy (excluding nonmelanoma carcinomas of the skin and carcinoma in situ cervix) unless in remission for ≥ 2 years.
10. Kaposi's Sarcoma.
11. Patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major blood vessels.
12. History of Stroke/Transient Ischemic Attack
13. Use of bleeding diathesis
14. Use of anti-coagulants
15. Patients with clinically significant cardiovascular disease including any of the following:
1. Significant cardiac conduction abnormalities (e.g., PR interval \> 0.24 sec or second or third degree AV block.
2. Uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg or diastolic BP \> 90 mm Hg.
3. Myocardial infarction, cardiac arrhythmia, or unstable angina within the past 6 months.
4. New York Heart Association grade II or greater congestive heart failure.
5. Serious cardiac arrhythmia requiring medication.
6. Grade II or greater peripheral vascular disease except episodes of ischemia \< 24 hours induration that are managed non-surgically and without permanent deficit
7. History of cerebrovascular accident within the past 6 months.
8. No significant traumatic injury within the past 28 days.
16. Uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements.
17. Patients with known HIV.
18. Patients with chronic Hepatitis B and C infection.
19. Patients with uncontrolled autoimmune diseases.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gradalis, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minal Barve, MD
Role: PRINCIPAL_INVESTIGATOR
Mary Crowley Cancer Research Centers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mary Crowley Cancer Research Centers
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL-PTL 112
Identifier Type: -
Identifier Source: org_study_id